JP2015501849A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501849A5 JP2015501849A5 JP2014548835A JP2014548835A JP2015501849A5 JP 2015501849 A5 JP2015501849 A5 JP 2015501849A5 JP 2014548835 A JP2014548835 A JP 2014548835A JP 2014548835 A JP2014548835 A JP 2014548835A JP 2015501849 A5 JP2015501849 A5 JP 2015501849A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- mntx
- administration
- rescue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 63
- IFGIYSGOEZJNBE-KNLJMPJLSA-N (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one;bromide Chemical compound [Br-].C[N+]1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)CC1CC1 IFGIYSGOEZJNBE-KNLJMPJLSA-N 0.000 claims 33
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 claims 23
- 229960002921 methylnaltrexone Drugs 0.000 claims 23
- 230000013872 defecation Effects 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 16
- 206010010774 Constipation Diseases 0.000 claims 12
- 208000030053 Opioid-Induced Constipation Diseases 0.000 claims 11
- 235000013305 food Nutrition 0.000 claims 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- 150000001450 anions Chemical class 0.000 claims 6
- JTESKNWFQRABFY-UHFFFAOYSA-M sodium;tetracosyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCCCCCCCOS([O-])(=O)=O JTESKNWFQRABFY-UHFFFAOYSA-M 0.000 claims 6
- 230000001684 chronic effect Effects 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 230000001965 increasing effect Effects 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 claims 4
- 235000012054 meals Nutrition 0.000 claims 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 4
- 230000003442 weekly effect Effects 0.000 claims 3
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 2
- 238000010521 absorption reaction Methods 0.000 claims 2
- 230000002411 adverse Effects 0.000 claims 2
- 150000008064 anhydrides Chemical class 0.000 claims 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 2
- 229960000913 crospovidone Drugs 0.000 claims 2
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 claims 2
- 230000037213 diet Effects 0.000 claims 2
- 235000005911 diet Nutrition 0.000 claims 2
- 229940124274 edetate disodium Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000029142 excretion Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 229940057948 magnesium stearate Drugs 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 229960005181 morphine Drugs 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 2
- 239000000454 talc Substances 0.000 claims 2
- 229910052623 talc Inorganic materials 0.000 claims 2
- 229940033134 talc Drugs 0.000 claims 2
- 210000001015 abdomen Anatomy 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161577654P | 2011-12-19 | 2011-12-19 | |
| US61/577,654 | 2011-12-19 | ||
| PCT/US2012/070612 WO2013096444A1 (en) | 2011-12-19 | 2012-12-19 | Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018197326A Division JP2019048820A (ja) | 2011-12-19 | 2018-10-19 | メチルナルトレキソンの経口組成物を用いたオピオイド誘導性便秘症の治療及び予防のための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015501849A JP2015501849A (ja) | 2015-01-19 |
| JP2015501849A5 true JP2015501849A5 (enExample) | 2016-02-12 |
Family
ID=48669445
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548835A Pending JP2015501849A (ja) | 2011-12-19 | 2012-12-19 | メチルナルトレキソンの経口組成物を用いたオピオイド誘導性便秘症の治療及び予防のための方法 |
| JP2018197326A Pending JP2019048820A (ja) | 2011-12-19 | 2018-10-19 | メチルナルトレキソンの経口組成物を用いたオピオイド誘導性便秘症の治療及び予防のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018197326A Pending JP2019048820A (ja) | 2011-12-19 | 2018-10-19 | メチルナルトレキソンの経口組成物を用いたオピオイド誘導性便秘症の治療及び予防のための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20130317050A1 (enExample) |
| EP (1) | EP2793888A4 (enExample) |
| JP (2) | JP2015501849A (enExample) |
| KR (1) | KR20140107540A (enExample) |
| CN (2) | CN110384701A (enExample) |
| AU (3) | AU2012359013A1 (enExample) |
| BR (1) | BR112014014805A2 (enExample) |
| CA (1) | CA2859203C (enExample) |
| IL (1) | IL233266A0 (enExample) |
| MX (1) | MX2014007312A (enExample) |
| WO (1) | WO2013096444A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| WO2015191686A1 (en) * | 2014-06-10 | 2015-12-17 | Salix Pharmaceuticals, Inc. | Methods of administering methylnaltrexone |
| EP3206491B1 (en) * | 2014-10-17 | 2019-11-27 | Salix Pharmaceuticals, Inc. | Use of methylnaltrexone to attenuate tumor progression |
| KR20180123136A (ko) * | 2016-03-29 | 2018-11-14 | 코로나리콘셉츠 엘엘씨 | 변비 치료용 제제 |
| WO2023031955A1 (en) * | 2021-08-28 | 2023-03-09 | Redasani Vijayendrakumar Virendrakumar Ji | Oral pharmaceutical compositions of methylnaltrexone and salt thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS601128A (ja) * | 1983-06-15 | 1985-01-07 | Shionogi & Co Ltd | 作用持続型セフアクロル製剤 |
| US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
| US20050176685A1 (en) * | 2002-04-05 | 2005-08-11 | Daifotis Anastasia G. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| SE0303135D0 (sv) * | 2003-11-25 | 2003-11-25 | Lipocore Holding Ab | Controlled food effect composition |
| EP1906951A4 (en) * | 2005-07-01 | 2009-05-27 | Dynogen Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL HYPOMOTILITY AND RELEVANT DISEASES |
| EA201001643A1 (ru) * | 2008-05-07 | 2011-06-30 | Нектар Терапеутикс | Пероральное введение периферически действующих опиоидных антагонистов |
| CN101845047B (zh) * | 2009-12-31 | 2011-12-07 | 南京臣功制药有限公司 | 一种溴甲基纳曲酮的制备方法 |
| KR101913102B1 (ko) * | 2010-03-11 | 2018-10-31 | 와이어쓰 엘엘씨 | 메틸날트렉손의 경구 제형 및 친유성 염 |
-
2012
- 2012-12-19 BR BR112014014805A patent/BR112014014805A2/pt not_active Application Discontinuation
- 2012-12-19 CA CA2859203A patent/CA2859203C/en active Active
- 2012-12-19 CN CN201910609611.9A patent/CN110384701A/zh active Pending
- 2012-12-19 JP JP2014548835A patent/JP2015501849A/ja active Pending
- 2012-12-19 US US13/720,235 patent/US20130317050A1/en not_active Abandoned
- 2012-12-19 AU AU2012359013A patent/AU2012359013A1/en not_active Abandoned
- 2012-12-19 MX MX2014007312A patent/MX2014007312A/es unknown
- 2012-12-19 WO PCT/US2012/070612 patent/WO2013096444A1/en not_active Ceased
- 2012-12-19 CN CN201280070087.9A patent/CN104254332A/zh active Pending
- 2012-12-19 KR KR1020147020310A patent/KR20140107540A/ko not_active Ceased
- 2012-12-19 EP EP12860187.9A patent/EP2793888A4/en not_active Withdrawn
-
2014
- 2014-06-19 IL IL233266A patent/IL233266A0/en unknown
-
2017
- 2017-11-06 AU AU2017258808A patent/AU2017258808A1/en not_active Abandoned
-
2018
- 2018-10-19 JP JP2018197326A patent/JP2019048820A/ja active Pending
- 2018-11-30 US US16/206,570 patent/US20190231771A1/en not_active Abandoned
-
2019
- 2019-05-27 AU AU2019203694A patent/AU2019203694A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leppert | Oxycodone/naloxone in the management of patients with pain and opioid–induced bowel dysfunction | |
| JP6196041B2 (ja) | 大うつ病を有する患者において減量療法を提供する方法 | |
| JP2010518122A5 (enExample) | ||
| JP2011190259A5 (enExample) | ||
| JP2015501849A5 (enExample) | ||
| US20080206333A1 (en) | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine | |
| US20090088404A1 (en) | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine | |
| US20090197824A1 (en) | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine | |
| JP2020503269A5 (enExample) | ||
| WO2015010449A1 (zh) | 使用维生素b组合物促进胃肠系统动力的方法 | |
| FI3884947T3 (fi) | Lääkkeen hyötyosuuden lisääminen naltreksonihoidossa | |
| JP6232135B2 (ja) | 疼痛およびオピオイドによる腸機能障害症候群の治療のためのヒドロモルホンおよびナロキソン | |
| JP2021509395A5 (enExample) | ||
| RU2016117186A (ru) | Комбинированная композиция, содержащая тадалафил и амлодипин | |
| JP2020500864A5 (enExample) | ||
| WO2017076271A1 (zh) | 奥贝胆酸和小檗碱的复方组合物及其应用 | |
| CN109789147A (zh) | 用于治疗非酒精性脂肪性肝病的药物组合物及方法 | |
| JP2016505050A5 (enExample) | ||
| US20090118211A1 (en) | Compositions and Methods for Enhancement of Sexual Function | |
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| JP2008533022A5 (enExample) | ||
| WO2023135595A1 (en) | Combinations with psilocybin for treating gastrointestinal diseases or disorders | |
| JP2014510780A5 (enExample) | ||
| US20150110865A1 (en) | Cns stimulant and opioid receptor antagonist combination as a non-addictive, non-aversive and synergistic anti-obesity treatment | |
| JP2013540732A5 (enExample) |